SURVYR

IRTC

iRhythm Holdings, Inc.
$123.99
+$0.24 (0.19%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-45%-30%-14%+1%+16%Oct 2025Oct 2026Apr 202652w high $212.0052w low $100.70
IRTCSPY
Wall St. Highest PT $196.00 (+58.1%) Wall St. Avg PT $171.33 (+38.2%)
$102$142$183$223$264POC $117Hi $196Avg $171
Underwater Drawdown %Max DD -46.2%Current -34.5%
0.0%-46.2%
Relative Strength vs SPY-46.1% vs SPYUnderperforming
+67%0%-67%
1W
+$10.44 (9.19%)
1M
+$11.39 (10.12%)
3M
+$1.55 (1.27%)
6M
+$3.24 (2.68%)
YTD
−$53.45 (30.12%)
1Y
−$58.68 (32.12%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
15 analysts · mean score 1.19
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$123.99
Average target$171.33
+$47.34 (+38.2%) upsideaverage target vs current price
CurrentAverageMedian
Low$140.00
Median$171.33
High$196.00
12-month Wall Street target range
Recent analyst rating changes · 8
Initiated
2026-10-16 · Piper Sandler started covering IRTC at Overweight
Reiterated
2026-10-06 · Wells Fargo reiterated Overweight on IRTC
Reiterated
2026-10-06 · Freedom Capital Markets reiterated Buy on IRTC
Reiterated
2026-10-05 · Needham reiterated Buy on IRTC
Reiterated
2026-08-18 · Wells Fargo reiterated Overweight on IRTC
Reiterated
2026-08-10 · Truist Securities reiterated Buy on IRTC
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$3.7B
P/E (next 12 months, estimated)91.2
52-week range$100.70 – $212.00
Revenue growth (latest quarter vs a year ago)+20.1%
Dividend yieldNo dividend
Analyst consensusStrong Buy (15)
Average analyst price target$171.33 (+38%)

What they do

iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.

Healthcare · Medical Devices
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for IRTC yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

IRTC earningsNext report in 7 days
Next report · quarter Sep 2026
Thu Nov 5, 2026After the close
EPS consensus$0.05 range -$0.08–$0.14
Revenue consensus$222.2M 15 analysts
Last 4 quarters · EPS vs estimate
Aug 6, 2026$0.58est $0.04+1258.0%Above estimates
Apr 30, 2026-$0.35est -$0.64+45.3%Above estimates
Feb 19, 2026$0.29est $0.06+410.6%Above estimates
Oct 30, 2025-$0.06est -$0.28+78.8%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-21 18:23:20 ET
24-1025-0225-0525-0725-1026-0226-0426-08-1.260.58
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$224.2M+20.1%
2026-03-31$199.4M–
2025-12-31$208.9M–
2025-09-30$192.9M–
2025-06-30$186.7M–

News & catalysts

More news
2 healthcare stocks with solid fundamentals and 1 we question
StockStory · Oct 27
Rating changes
Initiated
2026-10-16 · Piper Sandler started covering IRTC at Overweight
Reiterated
2026-10-06 · Wells Fargo reiterated Overweight on IRTC
Reiterated
2026-10-06 · Freedom Capital Markets reiterated Buy on IRTC
Reiterated
2026-10-05 · Needham reiterated Buy on IRTC
Reiterated
2026-08-18 · Wells Fargo reiterated Overweight on IRTC
Reiterated
2026-08-10 · Truist Securities reiterated Buy on IRTC

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Wilson Daniel G.
Chief Financial Officer · 2026-09-02
Sell
$94.2K
Turakhia Minang
CHIEF MED/SCI OFCR EVP ADVTECH · 2026-08-10
Sell
$884.2K
Shrishrimal Sumi
EVP, Chief Risk Officer · 2026-08-10
Sell
$669.6K
Patterson Chad
CHIEF COMM & PRODUCT OFFICER · 2026-08-10
Sell
$884.2K
Murphy Patrick Michael
CBO and CLO · 2026-08-10
Sell
$884.2K
Blackford Quentin S.
Director, President and CEO · 2026-08-10
Sell
$3.3M
Patterson Chad
CHIEF COMM & PRODUCT OFFICER · 2026-08-03
Sell
$331.2K
Rodda Julianne
EVP, CHIEF PEOPLE OFFICER · 2026-08-03
Sell
$257.9K
Smith Mervin
EVP Strategic Business Ops · 2026-08-03
Sell
$75.3K

Stats refreshed 2026-10-21 18:23:20 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026